Renal Biomarker Market: Rising Prevalence of Renal Diseases Fuelling Demand for Renal Biomarkers: Global Industry Analysis and Opportunity Assessment, 2016-2026

Healthcare, Pharmaceuticals and Medical devices
No. of Pages: 190

Published: Nov, 2016
Report Code: REP-GB-1731
Format:

An Incisive, In-depth Analysis on the Renal Biomarker Market

This study offers a comprehensive, 360 degree analysis on the Renal Biomarker market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Renal Biomarker market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Request a sample

Ask An Analyst

Request Special Price

Request Methodology

Kidney diseases are one of the leading causes of death worldwide. The incidence of chronic kidney diseases is rapidly rising especially in the elderly population due to increase in life expectancy of general population and improvements in medical management services. However, diabetes and hypertension remain the leading cause of renal diseases. Biomarkers are measurable indicators reflecting physiological and pharmacological progression of disease state. Recent advances in molecular biology have resulted in the development of novel biomarkers for the renal function. Extensive R&D by biomarker manufacturers has led to identification of novel renal biomarkers to deliver better diagnostic accuracy and improve patient outcomes.

Market forecast

Revenue from the global renal biomarker market is projected to register a CAGR of 7.0% during the forecast period (2016 – 2026) and reach a market valuation of US$ 1,770.3 Mn by the end of 2026.

Rising prevalence of renal diseases primary driver boosting market growth

Growth of the global renal biomarker market is mainly driven by rising prevalence of various renal diseases coupled with an ageing population worldwide. Also, there has been an increase in the adult population with chronic kidney diseases, primarily attributed to a rising prevalence of conditions such as diabetes and high blood pressure. Other prominent growth factors include large number of clinical trials in the novel renal biomarker and drug development space and penetration of various cost-effective, reliable, and rapid technologically driven diagnostic protocols in clinical practice. However, use of unreliable imperfect gold standard for renal disease diagnosis and lack of sensitivity and specificity in current renal biomarkers are some of the factors restraining the growth of the market over the forecast period.

Current trends governing the global renal biomarker market include the possible use of renal biomarkers in personalised medicine and drug development and a growing popularity of non-invasive renal biomarkers.

Market segmentation

By Biomarker Type	By Diagnostic Technique	By End User	By Region
Functional Biomarker Serum Creatinine Serum Cystatin C Urine Albumin Up-Regulated Proteins Neutrophil gelatinase-associated lipocalin Kidney injury molecule 1 Interleukin 18 Others	Enzyme Linked Immunosorbent Assay Particle-Enhanced Turbidimetric Immunoassay Colorimetric Assay Chemiluminescent Enzyme Immunoassay Liquid Chromatography-Mass Spectrometry	Diagnostic Labs Outpatient Clinics Research Centres Hospitals	North America Latin America Western Europe Eastern Europe Asia Pacific Excluding Japan (APEJ) Japan Middle East & Africa (MEA)

Functional Biomarker type segment expected to remain the dominant segment over the forecast period

The Functional Biomarker segment is anticipated to account for a market value share of 52.3% by the end of 2016 and is expected to retain its dominance throughout the forecast period. The Up-Regulated Proteins segment is estimated to account for 33.8% market share in terms of value by 2016 end.

Enzyme Linked Immunosorbent Assay diagnostic technique segment estimated to hold the highest market share throughout the forecast period

The Enzyme Linked Immunosorbent Assay segment is anticipated to register a CAGR of 8.1% over the forecast period and is expected to register high Y-o-Y growth rates from 2016 to 2026. The Particle-Enhanced Turbidimetric Immunoassay segment is estimated to be the second largest segment in terms of value, holding a market value share of 21.0% by 2016 end.

Diagnostic Labs end user segment expected to witness highest growth in terms of revenue throughout the forecast period

The Diagnostic Labs segment is estimated to account for 34.2% market share of the global renal biomarker market in revenue terms by 2016 end and is expected to register high Y-o-Y growth rates throughout the forecast period. The Outpatient Clinics segment is anticipated to register a CAGR of 7.2% during the forecast period.

North America renal biomarker market expected to register high Y-o-Y growth throughout the forecast period

The North America regional market is estimated to account for 32.2% revenue share of the global renal biomarker market by 2016 end. Western Europe is estimated to hold the second largest market share of 21.1% by 2016 end.

renal biomarker market_image for preview analysis

Leading market players are emphasising on product innovation and strategic acquisitions to increase market share

Beckman Coulter, Inc. (Danaher Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S, Astute Medical, Inc., and Randox Laboratories Ltd. are some of the key players operating in the global renal biomarker market. Top market companies are focussing on increasing their presence in high-growth emerging markets through structured investments in R&D and technological innovation.

Future Market Insights examines the global renal biomarker market for the period 2016–2026 in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” The primary objective of the report is to offer updates and in-depth analysis of market opportunities in the global renal biomarker market. The report offers a global market forecast in terms of value for the next 10 years.

Report description

To understand and assess opportunities in this market, the report is categorically split under four sections based on market segmentation – by biomarker type, diagnostic technique, end user, and region. The report analyses the global renal biomarker market in terms of market value (US$ Mn). The report begins with an overview of various types of renal diseases and addressable biomarker followed by a market forecast for the period 2016 – 2026. We have also presented a detailed analysis of key trends and drivers from the economic and supply and demand perspectives, market restraints, and trends likely to impact the global renal biomarker market. The subsequent sections analyse the global renal biomarker market on the basis of biomarker type, diagnostic technique, end user, and region and present a comprehensive forecast in terms of value for the next 10 years. Our study further discusses the key trends across the various assessed regions and analyses the degree to which drivers are influencing the market in each region.

In the final section of the report, we have included the global renal biomarker market competitive landscape to provide report audiences with a dashboard view of key renal biomarker providers, their presence in the global renal biomarker market, and key differentiators. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the global renal biomarker market. We have further profiled the leading players on the basis of various attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview to evaluate their long- and short-term strategies, key offerings, and recent developments in the global renal biomarker market.

Research methodology

We have leveraged extensive secondary research to ascertain overall market size and top industry players. To arrive at the market size, the report considers average price of renal biomarker assays across geographies. The forecast presented here assesses the total revenue of the global renal biomarker market. When developing the market forecast, the starting point involves sizing the current market, which forms the basis for forecasting how the market is anticipated to take shape in the near future. Given the characteristics of the market, we have triangulated the outcome on the basis of supply and demand side analysis. The report also takes into consideration year-on-year growth to understand the predictability of the market and to identify the right opportunities across the global renal biomarker market.

Further, the different market segments have been analysed in terms of Basis Point Share (BPS) to understand individual segments’ relative contribution to market growth. This detailed level of information is important for the identification of various key trends governing the global renal biomarker market. Another key feature of our report is the analysis of the global renal biomarker market by region, biomarker type, diagnostic technique, and end user, and its revenue forecast in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the global renal biomarker market. Further, to understand key segments in terms of growth and performance in the global renal biomarker market, Future Market Insights has developed a market attractiveness index to help providers identify existing market opportunities across the global renal biomarker market.

Renal Biomarker Market Reports - Table of Contents

1. Executive Summary

2. Market Introduction

2.1. Market Definition

2.2. Market Taxonomy

3. Global Renal Biomarker Market Analysis Scenario

3.1. Market Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.1.2. Absolute $ Opportunity

3.2. Market Overview

4. Market Dynamics

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Forecast Factors – Relevance and Impact

4.6. Diseases Epidemiology

5. Global Renal Biomarker Market Analysis and Forecasts, By Biomarker Type

5.1. Introduction

5.2. Basis Point Share (BPS) Analysis By Biomarker Type

5.3. Y-o-Y Growth Projections By Biomarker Type

5.4. Market Value Forecast By Biomarker Type , 2015–2026

5.4.1. Functional Biomarker

5.4.1.1. Serum Creatinine

5.4.1.2. Serum Cystatin C

5.4.1.3. Urine Albumin

5.4.2. Up-Regulated Proteins

5.4.2.1. Neutrophil Gelatinase-Associated Lipocalin

5.4.2.2. Kidney Injury Molecule-1

5.4.2.3. Interleukin-18

5.4.3. Others

5.5. Prominent Trends

5.6. Market Attractiveness By Biomarker Type

6. Global Renal Biomarker Market Analysis and Forecasts, By Diagnostic Technique

6.1. Introduction

6.2. Basis Point Share (BPS) Analysis By Diagnostic Technique

6.3. Y-o-Y Growth Projections By Diagnostic Technique

6.4. Market Value Forecast By Diagnostic Technique , 2015–2026

6.4.1. Enzyme Linked Immunosorbent Assay (ELISA)

6.4.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

6.4.3. Colorimetric Assay

6.4.4. Chemiluminescent Enzyme Immunoassay (CLIA)

6.4.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

6.5. Prominent Trends

6.6. Market Attractiveness By Diagnostic Technique

7. Global Renal Biomarker Market Analysis and Forecasts, By End User

7.1. Introduction

7.2. Basis Point Share (BPS) Analysis By End User

7.3. Y-o-Y Growth Projections By End User

7.4. Market Value Forecast By End User , 2015–2026

7.4.1. Diagnostic Labs

7.4.2. Outpatient Clinics

7.4.3. Research Centers

7.4.4. Hospitals

7.5. Prominent Trends

7.6. Market Attractiveness By End User

8. Global Renal Biomarker Market Analysis and Forecasts, By Region

8.1. Basis Point Share (BPS) Analysis By Country

8.2. Y-o-Y Growth Projections By Country

8.3. Market Value Forecast By Region

8.3.1. North America

8.3.2. Latin America

8.3.3. Western Europe

8.3.4. Eastern Europe

8.3.5. Asia Pacific Excluding Japan (APEJ)

8.3.6. Japan

8.3.7. Middle East and Africa (MEA)

8.4. Market Attractiveness By Country/Region

9. North America Renal Biomarker Market Analysis and Forecast

9.1. Introduction

9.1.1. Basis Point Share (BPS) Analysis By Country

9.1.2. Y-o-Y Growth Projections By Country

9.1.3. Key Regulations

9.2. Market Value Forecast By Biomarker Type , 2015–2026

9.2.1. Functional Biomarker

9.2.1.1. Serum Creatinine

9.2.1.2. Serum Cystatin C

9.2.1.3. Urine Albumin

9.2.2. Up-Regulated Proteins

9.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

9.2.2.2. Kidney Injury Molecule-1

9.2.2.3. Interleukin-18

9.2.3. Others

9.3. Market Value Forecast By Diagnostic Technique , 2015–2026

9.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

9.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

9.3.3. Colorimetric Assay

9.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

9.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

9.4. Market Value Forecast By End User , 2015–2026

9.4.1. Diagnostic Labs

9.4.2. Outpatient Clinics

9.4.3. Research Centers

9.4.4. Hospitals

9.5. Market Value Forecast By Country , 2015–2026

9.5.1. The U.S.

9.5.2. Canada

9.6. Market Attractiveness Analysis

9.6.1. By Biomarker Type

9.6.2. By Diagnostic Technique

9.6.3. By End User

9.6.4. By Country

9.7. Prominent Trends

9.8. Drivers and Restraints: Impact Analysis

10. Latin America Renal Biomarker Market Analysis and Forecast

10.1.Introduction

10.1.1. Basis Point Share (BPS) Analysis By Country

10.1.2. Y-o-Y Growth Projections By Country

10.1.3. Key Regulations

10.2.Market Value Forecast By Biomarker Type , 2015–2026

10.2.1. Functional Biomarker

10.2.1.1. Serum Creatinine

10.2.1.2. Serum Cystatin C

10.2.1.3. Urine Albumin

10.2.2. Up-Regulated Proteins

10.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

10.2.2.2. Kidney Injury Molecule-1

10.2.2.3. Interleukin-18

10.2.3. Others

10.3.Market Value Forecast By Diagnostic Technique , 2015–2026

10.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

10.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

10.3.3. Colorimetric Assay

10.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

10.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

10.4.Market Value Forecast By End User , 2015–2026

10.4.1. Diagnostic Labs

10.4.2. Outpatient Clinics

10.4.3. Research Centers

10.4.4. Hospitals

10.5.Market Value Forecast By Country , 2015–2026

10.5.1. Brazil

10.5.2. Mexico

10.5.3. Rest of Latin America

10.6.Market Attractiveness Analysis

10.6.1. By Biomarker Type

10.6.2. By Diagnostic Technique

10.6.3. By End User

10.6.4. By Country

10.7. Prominent Trends

10.8. Drivers and Restraints: Impact Analysis

11. Western Europe Renal Biomarker Market Analysis and Forecast

11.1.Introduction

11.1.1. Basis Point Share (BPS) Analysis By Country

11.1.2. Y-o-Y Growth Projections By Country

11.1.3. Key Regulations

11.2.Market Value Forecast By Biomarker Type , 2015–2026

11.2.1. Functional Biomarker

11.2.1.1. Serum Creatinine

11.2.1.2. Serum Cystatin C

11.2.1.3. Urine Albumin

11.2.2. Up-Regulated Proteins

11.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

11.2.2.2. Kidney Injury Molecule-1

11.2.2.3. Interleukin-18

11.2.3. Others

11.3.Market Value Forecast By Diagnostic Technique , 2015–2026

11.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

11.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

11.3.3. Colorimetric Assay

11.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

11.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

11.4.Market Value Forecast By End User , 2015–2026

11.4.1. Diagnostic Labs

11.4.2. Outpatient Clinics

11.4.3. Research Centers

11.4.4. Hospitals

11.5.Market Value Forecast By Country , 2015–2026

11.5.1. Germany

11.5.2. France

11.5.3. Italy

11.5.4. Spain

11.5.5. The U.K.

11.5.6. BENELUX

11.5.7. Rest of Western Europe

11.6.Market Attractiveness Analysis

11.6.1. By Biomarker Type

11.6.2. By Diagnostic Technique

11.6.3. By End User

11.6.4. By Country

11.7. Prominent Trends

11.8. Drivers and Restraints: Impact Analysis

12. Eastern Europe Renal Biomarker Market Analysis and Forecast

12.1.Introduction

12.1.1. Basis Point Share (BPS) Analysis By Country

12.1.2. Y-o-Y Growth Projections By Country

12.1.3. Key Regulations

12.2.Market Value Forecast By Biomarker Type , 2015–2026

12.2.1. Functional Biomarker

12.2.1.1. Serum Creatinine

12.2.1.2. Serum Cystatin C

12.2.1.3. Urine Albumin

12.2.2. Up-Regulated Proteins

12.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

12.2.2.2. Kidney Injury Molecule-1

12.2.2.3. Interleukin-18

12.2.3. Others

12.3.Market Value Forecast By Diagnostic Technique , 2015–2026

12.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

12.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

12.3.3. Colorimetric Assay

12.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

12.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

12.4.Market Value Forecast By End User , 2015–2026

12.4.1. Diagnostic Labs

12.4.2. Outpatient Clinics

12.4.3. Research Centers

12.4.4. Hospitals

12.5.Market Value Forecast By Country , 2015–2026

12.5.1. Russia

12.5.2. Poland

12.5.3. Rest of Eastern Europe

12.6.Market Attractiveness Analysis

12.6.1. By Biomarker Type

12.6.2. By Diagnostic Technique

12.6.3. By End User

12.6.4. By Country

12.7. Prominent Trends

12.8. Drivers and Restraints: Impact Analysis

13. Asia Pacific Excluding Japan (APEJ) Renal Biomarker Market Analysis and Forecast

13.1.Introduction

13.1.1. Basis Point Share (BPS) Analysis By Country

13.1.2. Y-o-Y Growth Projections By Country

13.1.3. Key Regulations

13.2.Market Value Forecast By Biomarker Type , 2015–2026

13.2.1. Functional Biomarker

13.2.1.1. Serum Creatinine

13.2.1.2. Serum Cystatin C

13.2.1.3. Urine Albumin

13.2.2. Up-Regulated Proteins

13.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

13.2.2.2. Kidney Injury Molecule-1

13.2.2.3. Interleukin-18

13.2.3. Others

13.3.Market Value Forecast By Diagnostic Technique , 2015–2026

13.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

13.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

13.3.3. Colorimetric Assay

13.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

13.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

13.4.Market Value Forecast By End User , 2015–2026

13.4.1. Diagnostic Labs

13.4.2. Outpatient Clinics

13.4.3. Research Centers

13.4.4. Hospitals

13.5.Market Value Forecast By Country , 2015–2026

13.5.1. China

13.5.2. India

13.5.3. ASEAN

13.5.4. Australia and New Zealand

13.5.5. Rest of APEJ

13.6.Market Attractiveness Analysis

13.6.1. By Biomarker Type

13.6.2. By Diagnostic Technique

13.6.3. By End User

13.6.4. By Country

13.7. Prominent Trends

13.8. Drivers and Restraints: Impact Analysis

14. Japan Renal Biomarker Market Analysis and Forecast

14.1.Introduction

14.1.1. Basis Point Share (BPS) Analysis By Country

14.1.2. Y-o-Y Growth Projections By Country

14.1.3. Key Regulations

14.2.Market Value Forecast By Biomarker Type , 2015–2026

14.2.1. Functional Biomarker

14.2.1.1. Serum Creatinine

14.2.1.2. Serum Cystatin C

14.2.1.3. Urine Albumin

14.2.2. Up-Regulated Proteins

14.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

14.2.2.2. Kidney Injury Molecule-1

14.2.2.3. Interleukin-18

14.2.3. Others

14.3.Market Value Forecast By Diagnostic Technique , 2015–2026

14.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

14.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

14.3.3. Colorimetric Assay

14.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

14.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

14.4.Market Value Forecast By End User , 2015–2026

14.4.1. Diagnostic Labs

14.4.2. Outpatient Clinics

14.4.3. Research Centers

14.4.4. Hospitals

14.5.Market Attractiveness Analysis

14.5.1. By Biomarker Type

14.5.2. By Diagnostic Technique

14.5.3. By End User

14.6. Prominent Trends

14.7. Drivers and Restraints: Impact Analysis

15. Middle East and Africa (MEA) Renal Biomarker Market Analysis and Forecast

15.1.Introduction

15.1.1. Basis Point Share (BPS) Analysis By Country

15.1.2. Y-o-Y Growth Projections By Country

15.1.3. Key Regulations

15.2.Market Value Forecast By Biomarker Type , 2015–2026

15.2.1. Functional Biomarker

15.2.1.1. Serum Creatinine

15.2.1.2. Serum Cystatin C

15.2.1.3. Urine Albumin

15.2.2. Up-Regulated Proteins

15.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

15.2.2.2. Kidney Injury Molecule-1

15.2.2.3. Interleukin-18

15.2.3. Others

15.3.Market Value Forecast By Diagnostic Technique , 2015–2026

15.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

15.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

15.3.3. Colorimetric Assay

15.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

15.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

15.4.Market Value Forecast By End User , 2015–2026

15.4.1. Diagnostic Labs

15.4.2. Outpatient Clinics

15.4.3. Research Centers

15.4.4. Hospitals

15.5.Market Value Forecast By Country , 2015–2026

15.5.1. GCC

15.5.2. South Africa

15.5.3. Rest of MEA

15.6.Market Attractiveness Analysis

15.6.1. By Biomarker Type

15.6.2. By Diagnostic Technique

15.6.3. By End User

15.6.4. By Country

15.7. Prominent Trends

15.8. Drivers and Restraints: Impact Analysis

16. Competition Landscape

16.1.Competition Dashboard

16.2.Market Share Analysis By Company (2015)

16.3.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

16.3.1. Beckman Coulter, Inc. (Danaher Corporation)

16.3.2. Thermo Fisher Scientific Inc.

16.3.3. Abbott Laboratories

16.3.4. BIOPORTO A/S

16.3.5. Astute Medical, Inc.

16.3.6. Randox Laboratories Ltd.

17. Assumptions and Acronyms Used

18. Research Methodology

Renal Biomarker Market Reports - List of Tables

Table 1: Global Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026

Table 2: Global Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026

Table 3: Global Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026

Table 4: Global Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Region, 2015–2026

Table 5: North America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 6: North America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026

Table 7: North America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026

Table 8: North America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 9: Latin America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 10: Latin America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026

Table 11: Latin America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026

Table 12: Latin America Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 13: Western Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 14: Western Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026

Table 15: Western Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026

Table 16: Western Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 17: Eastern Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 18: Eastern Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026

Table 19: Eastern Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026

Table 20: Eastern Europe Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 21: APEJ Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 22: APEJ Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026

Table 23: APEJ Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026

Table 24: APEJ Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 25: Japan Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026

Table 26: Japan Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026

Table 27: Japan Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 28: MEA Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 29: MEA Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Biomarker Type, 2015–2026

Table 30: MEA Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By Diagnostic Technique, 2015–2026

Table 31: MEA Renal Biomarker Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Renal Biomarker Market Reports - List of Figures

Figure 1: Global Renal Biomarker Market Share Analysis (%) By Biomarker Type, 2016, 2021 & 2026

Figure 2: Global Renal Biomarker Market Y-o-Y Growth (%) By Biomarker Type, 2015–2026

Figure 3: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Functional Biomarker Type Segment, 2015 – 2026

Figure 4: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Up-Regulated Proteins Biomarker Type Segment, 2015 – 2026

Figure 5: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Other Biomarker Type Segment, 2015 – 2026

Figure 6: Global Renal Biomarker Market Attractiveness Analysis By End User, 2016–2026

Figure 7: Global Renal Biomarker Market Value Share Analysis (%) By Diagnostic Technique, 2016, 2021 & 2026

Figure 8: Global Renal Biomarker Market Y-o-Y Growth (%) By Diagnostic Technique, 2015–2026

Figure 9: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Enzyme Linked Immunosorbent Assay Diagnostic Technique Segment, 2015 – 2026

Figure 10: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Particle-Enhanced Turbidimetric Immunoassay Diagnostic Technique Segment, 2015 – 2026

Figure 11: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Colorimetric Assay Diagnostic Technique Segment, 2015 – 2026

Figure 12: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Chemiluminescent Enzyme Immunoassay Diagnostic Technique Segment, 2015 – 2026

Figure 13: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Liquid Chromatography-Mass Spectrometry Diagnostic Technique Segment, 2015 – 2026

Figure 14: Global Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016–2026

Figure 15: Global Renal Biomarker Market Value Share Analysis (%) By End User, 2016, 2021 & 2026

Figure 16: Global Renal Biomarker Market Y-o-Y Growth (%) By End User, 2015–2026

Figure 17: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Hospitals End User Segment, 2015 – 2026

Figure 18: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Research Centers End User Segment, 2015 – 2026

Figure 19: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Outpatient Clinics End User Segment, 2015 – 2026

Figure 20: Global Renal Biomarker Market Absolute $ Opportunity (US$ Mn) By Diagnostic Labs End User Segment, 2015 – 2026

Figure 21: Global Renal Biomarker Market Attractiveness Analysis By End User, 2016–2026

Figure 22: Global Renal Biomarker Market Share Analysis (%) By Region, 2016, 2021 & 2026

Figure 23: Global Renal Biomarker Market Y-o-Y Growth (%) By Region, 2015–2026

Figure 24: North America Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 25: Latin America Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 26: Western Europe Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 27: Eastern Europe Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 28: APEJ Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 29: Japan Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 30: MEA Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 31: Global Renal Biomarker Market Attractiveness Analysis By Region, 2016–2026

Figure 32: North America Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026

Figure 33: North America Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 34: U.S. Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 35: Canada Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 36: North America Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026

Figure 37: North America Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026

Figure 38: North America Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026

Figure 39: North America Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026

Figure 40: Latin America Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026

Figure 41: Latin America Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 42: Brazil Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 43: Mexico Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 44: Rest of Latin America Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 45: Latin America Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026

Figure 46: Latin America Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026

Figure 47: Latin America Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026

Figure 48: Latin America Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026

Figure 49: Western Europe Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026

Figure 50: Western Europe Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 51: Germany Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 52: France Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 53: Italy Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 54: Spain Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 55: The U.K. Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 56: BENELUX Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 57: Rest of Western Europe Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 58: Western Europe Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026

Figure 59: Western Europe Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026

Figure 60: Western Europe Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026

Figure 61: Western Europe Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026

Figure 62: Eastern Europe Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026

Figure 63: Eastern Europe Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 64: Russia Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 65: Poland Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 66: Rest of Eastern Europe Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 67: Eastern Europe Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026

Figure 68: Eastern Europe Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026

Figure 69: Eastern Europe Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026

Figure 70: Eastern Europe Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026

Figure 71: APEJ Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026

Figure 72: APEJ Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 73: China Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 74: India Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 75: ASEAN Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 76: Australia and New Zealand Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 77: Rest of APEJ Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 78: APEJ Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026

Figure 79: APEJ Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026

Figure 80: APEJ Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026

Figure 81: APEJ Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026

Figure 82: Japan Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026

Figure 83: Japan Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026

Figure 84: Japan Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026

Figure 85: MEA Renal Biomarker Market Share Analysis (%) By Country, 2016, 2021 & 2026

Figure 86: MEA Renal Biomarker Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 87: GCC Countries Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 88: South Africa Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 89: Rest of MEA Renal Biomarker Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 90: MEA Renal Biomarker Market Attractiveness Analysis By Country, 2016 – 2026

Figure 91: MEA Renal Biomarker Market Attractiveness Analysis By Biomarker Type, 2016 – 2026

Figure 92: MEA Renal Biomarker Market Attractiveness Analysis By Diagnostic Technique, 2016 – 2026

Figure 93: MEA Renal Biomarker Market Attractiveness Analysis By End User, 2016 – 2026

Need specific information?

Request customization Get market alerts Ask for regional data Ask for country-specific data

Discounts available for multiple report purchases.

Request discount

5 reasons to choose FMI

Digital Intelligence Solutions

We combine AI and human experience to deliver insights you can act upon

Global Reach

Our expertise spans the globe; we track developments in over 150 countries to offer you a holistic perspective

Pre-sales and After-sales Support

We don't believe in hard sell – we are with you throughout the entire journey to ensure all your expectations are met

Experienced Research Consultants

Our research consultants are not generalists, but experienced hands who understand the dynamics of their domains

24 x 7 Availability

Opportunities don't wait for convenient time zones – we are online, 24 x 7 to help your market research needs

Need Assistance

Call +44 (0) 20 3287 4268 (D)

Call + 44 (0) 20 7692 8790

Contact sales

Get in touch

Harish Tiwari

Global Head - Business Development

hari.t@futuremarketinsights.com

+44 (0) 20 3287 4268

Pranay Mhaisekar

Business Development

pranay@futuremarketinsights.com

+ 44 (0) 20 7692 8790

First Name

Business Email

Phone No.

Company Name

Job Title

Any Specific Request

6N6AM Security Code

Our Clients

Recommendations

CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Learn More

Analysis Synopsis Table of contents Tables Figures

Request Sample Ask An Analyst Request Special Price Request Methodology

Renal Biomarker Market: Rising Prevalence of Renal Diseases Fuelling Demand for Renal Biomarkers: Global Industry Analysis and Opportunity Assessment, 2016-2026

An Incisive, In-depth Analysis on the Renal Biomarker Market

Renal Biomarker Market Reports - Table of Contents

Renal Biomarker Market Reports - List of Tables